Works matching IS 03407004 AND DT 2023 AND VI 72 AND IP 8

Results: 27

Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 8, p. 2829, doi. 10.1007/s00262-023-03464-w

By:

Himuro, Hidetomo;
Nakahara, Yoshiro;
Igarashi, Yuka;
Kouro, Taku;
Higashijima, Naoko;
Matsuo, Norikazu;
Murakami, Shuji;
Wei, Feifei;
Horaguchi, Shun;
Tsuji, Kayoko;
Mano, Yasunobu;
Saito, Haruhiro;
Azuma, Koichi;
Sasada, Tetsuro

Publication type:

Article

Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cancer immunobiology.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 8, p. 2813, doi. 10.1007/s00262-023-03463-x

By:

Panni, Usman Y.;
Chen, Michael Y.;
Zhang, Felicia;
Cullinan, Darren R.;
Li, Lijin;
James, C. Alston;
Zhang, Xiuli;
Rogers, S.;
Alarcon, A.;
Baer, John M.;
Zhang, Daoxiang;
Gao, Feng;
Miller, Christopher A.;
Gong, Qingqing;
Lim, Kian-Huat;
DeNardo, David G.;
Goedegebuure, S. Peter;
Gillanders, William E.;
Hawkins, William G.

Publication type:

Article

Enhanced HPV16 E6/E7+ tumor eradication via induction of tumor-specific T cells by therapeutic vaccination with virosomes presenting synthetic long peptides.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 8, p. 2851, doi. 10.1007/s00262-023-03462-y

By:

Stegmann, Toon;
Wiekmeijer, Anna-Sophia;
Kwappenberg, Kitty;
van Duikeren, Suzanne;
Bhoelan, Farien;
Bemelman, Denzel;
Beenakker, Thomas J. M.;
Krebber, Willem-Jan;
Arens, Ramon;
Melief, Cornelis J. M.

Publication type:

Article

Sequential CAR T cell and targeted alpha immunotherapy in disseminated multiple myeloma.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 8, p. 2841, doi. 10.1007/s00262-023-03461-z

By:

Awuah, Dennis;
Minnix, Megan;
Caserta, Enrico;
Tandoh, Theophilus;
Adhikarla, Vikram;
Poku, Erasmus;
Rockne, Russell;
Pichiorri, Flavia;
Shively, John E.;
Wang, Xiuli

Publication type:

Article

Brachyury-targeted immunotherapy combined with gemcitabine against head and neck cancer.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 8, p. 2799, doi. 10.1007/s00262-023-03460-0

By:

Yamaki, Hidekiyo;
Kono, Michihisa;
Wakisaka, Risa;
Komatsuda, Hiroki;
Kumai, Takumi;
Hayashi, Ryusuke;
Sato, Ryosuke;
Nagato, Toshihiro;
Ohkuri, Takayuki;
Kosaka, Akemi;
Ohara, Kenzo;
Kishibe, Kan;
Takahara, Miki;
Hayashi, Tatsuya;
Kobayashi, Hiroya;
Katada, Akihiro

Publication type:

Article

Exploiting docetaxel-induced tumor cell necrosis with tumor targeted delivery of IL-12.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 8, p. 2783, doi. 10.1007/s00262-023-03459-7

By:

Franks, S. Elizabeth;
Santiago-Sanchez, Ginette S.;
Fabian, Kellsye P.;
Solocinski, Kristen;
Chariou, Paul L.;
Hamilton, Duane H.;
Kowalczyk, Joshua T.;
Padget, Michelle R.;
Gameiro, Sofia R.;
Schlom, Jeffrey;
Hodge, James W.

Publication type:

Article

Improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mRNA sequencing and single-cell RNA-sequencing.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 8, p. 2757, doi. 10.1007/s00262-023-03458-8

By:

Jang, Sung Ill;
Lee, Hyung Keun;
Chang, Eun-Ju;
Kim, Somi;
Kim, So Young;
Hong, In Young;
Kim, Jong Kyoung;
Lee, Hye Sun;
Yang, Juyeon;
Cho, Jae Hee;
Lee, Dong Ki

Publication type:

Article

Correction to: Increased TIGIT expressing NK cells with dysfunctional phenotype in AML patients correlated with poor prognosis.

Published in:

2023

By:

Liu, Guanfang;
Zhang, Qi;
Yang, Jingying;
Li, Xiaomin;
Xian, Luhua;
Li, Wenmin;
Lin, Ting;
Cheng, Juan;
Lin, Qiwen;
Xu, Xiuzhang;
Li, Qin;
Lin, Yu;
Zhou, Maohua;
Shen, Erxia

Publication type:

Correction Notice

Single-center phase 2 study of PD-1 inhibitor combined with DNA hypomethylation agent + CAG regimen in patients with relapsed/refractory acute myeloid leukemia.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 8, p. 2769, doi. 10.1007/s00262-023-03454-y

By:

Gao, Xiao-Ning;
Su, Yong-Feng;
Li, Meng-yue;
Jing, Yu;
Wang, Jun;
Xu, Lei;
Zhang, Lin-Lin;
Wang, An;
Wang, Yi-Zhi;
Zheng, Xuan;
Li, Yan-Fen;
Liu, Dai-Hong

Publication type:

Article

Cytokine profiling identifies circulating IL-6 and IL-15 as prognostic stratifiers in patients with non-small cell lung cancer receiving anti-PD-1/PD-L1 blockade therapy.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 8, p. 2717, doi. 10.1007/s00262-023-03453-z

By:

Inoue, Yusuke;
Inui, Naoki;
Karayama, Masato;
Asada, Kazuhiro;
Fujii, Masato;
Matsuura, Shun;
Uto, Tomohiro;
Hashimoto, Dai;
Matsui, Takashi;
Ikeda, Masaki;
Yasui, Hideki;
Hozumi, Hironao;
Suzuki, Yuzo;
Furuhashi, Kazuki;
Enomoto, Noriyuki;
Fujisawa, Tomoyuki;
Suda, Takafumi

Publication type:

Article

Massively recruited sTLR9+ neutrophils in rapidly formed nodules at the site of tumor cell inoculation and their contribution to a pro-tumor microenvironment.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 8, p. 2671, doi. 10.1007/s00262-023-03451-1

By:

Kou, Mengyuan;
Lu, Wenting;
Zhu, Mengru;
Qu, Kuo;
Wang, Liying;
Yu, Yongli

Publication type:

Article

Characterizing the tumor immune microenvironment of ependymomas using targeted gene expression profiles and RNA sequencing.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 8, p. 2659, doi. 10.1007/s00262-023-03450-2

By:

de Koning, W.;
Feenstra, F. F.;
Calkoen, F. G. J.;
van der Lugt, J.;
Kester, L. A.;
Mustafa, D. A. M.

Publication type:

Article

Safety and efficacy of the anti-PD1 immunotherapy with nivolumab in trichoblastic carcinomas.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 8, p. 2649, doi. 10.1007/s00262-023-03449-9

By:

Toulemonde, E.;
Chevret, S.;
Battistella, M.;
Neidhardt, E. M.;
Nardin, C.;
Le Du, F.;
Meyer, N.;
Véron, M.;
Gambotti, L.;
Lamrani-Ghaouti, A.;
Jamme, P.;
Chaffaut, C.;
De Pontville, M.;
Saada-Bouzid, E.;
Beylot-Barry, M.;
Simon, C.;
Jouary, T.;
Marabelle, A.;
Mortier, L.

Publication type:

Article

Phenotypic and functional analysis in HER2+ targeted therapy of human NK cell subpopulation according to the expression of FcεRIγ and NKG2C in breast cancer patients.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 8, p. 2687, doi. 10.1007/s00262-023-03448-w

By:

Bordignon, María B.;
Pesce Viglietti, Ayelén I.;
Juliá, Estefanía P.;
Sanchez, María B.;
Rölle, Alexander;
Mandó, Pablo;
Sabatini, Luciana;
Ostinelli, Alexis;
Rizzo, Manglio M.;
Barrio, María M.;
Mordoh, José;
Fainboim, Leonardo;
Levy, Estrella M.

Publication type:

Article

The pathogenetic significance of exhausted T cells in a mouse model of mature B cell neoplasms.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 8, p. 2635, doi. 10.1007/s00262-023-03447-x

By:

Shibamiya, Asuka;
Miyamoto-Nagai, Yurie;
Koide, Shuhei;
Oshima, Motohiko;
Rizq, Ola;
Aoyama, Kazumasa;
Nakajima-Takagi, Yaeko;
Kato, Rei;
Kayamori, Kensuke;
Isshiki, Yusuke;
Oshima-Hasegawa, Nagisa;
Muto, Tomoya;
Tsukamoto, Shokichi;
Takeda, Yusuke;
Koyama-Nasu, Ryo;
Chiba, Tetsuhiro;
Honda, Hiroaki;
Yokote, Koutaro;
Iwama, Atsushi;
Sakaida, Emiko

Publication type:

Article

Self-assembled nanoparticles based on DNA origami and a nitrated T helper cell epitope as a platform for the development of personalized cancer vaccines.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 8, p. 2741, doi. 10.1007/s00262-023-03446-y

By:

Kang, Yanliang;
Zhang, Wanli;
Yu, Qiumin;
Gao, Le;
Quan, Jiale;
Gu, Fangling;
Wu, Yuxin;
Tian, Yahong;
Wu, Zijie;
Shao, Shishuai;
Zhou, Hongyou;
Duan, Shukang;
Zhou, Yixiang;
Zhang, Li;
Gao, Xiangdong;
Tian, Hong;
Yao, Wenbing

Publication type:

Article

Nervous regulation: beta-2-adrenergic signaling in immune homeostasis, cancer immunotherapy, and autoimmune diseases.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 8, p. 2549, doi. 10.1007/s00262-023-03445-z

By:

Thapa, Sagarina;
Cao, Xuefang

Publication type:

Article

Cytotoxicity of CD19-CAR-NK92 cells is primarily mediated via perforin/granzyme pathway.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 8, p. 2573, doi. 10.1007/s00262-023-03443-1

By:

Althaus, Jonas;
Nilius-Eliliwi, Verena;
Maghnouj, Abdelouahid;
Döring, Sascha;
Schroers, Roland;
Hudecek, Michael;
Hahn, Stephan A.;
Mika, Thomas

Publication type:

Article

Engineered murine IL-21-secreting leukemia cells induce granzyme B+ T cells and CD4+CD44+CD62L− effector memory cells while suppressing regulatory T cells, leading to long-term survival.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 8, p. 2597, doi. 10.1007/s00262-023-03442-2

By:

Berger, Alexandra;
Colpitts, Sarah J.;
Zych, Morgan;
Paige, Christopher J.

Publication type:

Article

Identification of a novel immune checkpoint molecule V-set immunoglobulin domain-containing 4 that leads to impaired immunity infiltration in pancreatic ductal adenocarcinoma.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 8, p. 2701, doi. 10.1007/s00262-023-03438-y

By:

Jiang, Yongsheng;
Han, Lijie;
Yang, Jian;
Yang, Minwei;
Zhang, Jian;
Xue, Meilin;
Zhu, Youwei;
Xiong, Cheng;
Shi, Minmin;
Zhao, Shiwei;
Shen, Baiyong;
Xu, Zhiwei;
Jiang, Lingxi;
Chen, Hao

Publication type:

Article

Switchable CAR T cell strategy against osteosarcoma.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 8, p. 2623, doi. 10.1007/s00262-023-03437-z

By:

Hidalgo, Laura;
Somovilla-Crespo, Beatriz;
Garcia-Rodriguez, Patricia;
Morales-Molina, Alvaro;
Rodriguez-Milla, Miguel Angel;
Garcia-Castro, Javier

Publication type:

Article

Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 8, p. 2729, doi. 10.1007/s00262-023-03434-2

By:

Zhang, Qi;
Zhang, Jian;
Zhong, Haijun;
Yuan, Ying;
Yang, Lei;
Zhang, Qingyuan;
Ji, Dongmei;
Gong, Jifang;
Li, Jing;
Yao, Zhenling;
Qi, Chuan;
Wang, Jianming;
Lu, Lingmin;
Shi, Michael;
Qian, Xueming;
Shen, Lin;
Li, Jian;
Hu, Xichun

Publication type:

Article

Immunoreactivity to WT1 peptide vaccine is associated with prognosis in elderly patients with acute myeloid leukemia: follow-up study of randomized phase II trial of OCV-501, an HLA class II-binding WT1 polypeptide.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 8, p. 2865, doi. 10.1007/s00262-023-03432-4

By:

Naoe, Tomoki;
Saito, Akiko;
Hosono, Nahoko;
Kasahara, Senji;
Muto, Hideharu;
Hatano, Kaoru;
Ogura, Mizuki;
Masunari, Taro;
Tanaka, Masatsugu;
Usuki, Kensuke;
Ishikawa, Yuichi;
Ando, Koji;
Kondo, Yukio;
Takagi, Yusuke;
Takada, Satoru;
Ishikawa, Maho;
Choi, Ilseung;
Sano, Akihiro;
Nagai, Hirokazu

Publication type:

Article

Characteristic differences in the abundance of tumor-infiltrating lymphocytes and intratumoral developing T cells in thymoma, with special reference to PD-1 expression.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 8, p. 2585, doi. 10.1007/s00262-023-03431-5

By:

Furuya, Tatsuo;
Ishihara, Shunta;
Ogi, Hiroshi;
Masuda, Kyoko;
Shibata, Saya;
Nakazono, Chiaki;
Okada, Satoru;
Shimomura, Masanori;
Tando, So;
Yaoi, Takeshi;
Maeda, Yoshinobu;
Yamagishi, Masaaki;
Kawamoto, Hiroshi;
Itoh, Kyoko;
Inoue, Masayoshi

Publication type:

Article

Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 8, p. 2613, doi. 10.1007/s00262-023-03429-z

By:

Shimoda, Yukiko;
Yoshida, Tatsuya;
Miyakoshi, Jun;
Torasawa, Masahiro;
Tateishi, Akiko;
Matsumoto, Yuji;
Masuda, Ken;
Shinno, Yuki;
Okuma, Yusuke;
Goto, Yasushi;
Horinouchi, Hidehito;
Yamamoto, Noboru;
Ohe, Yuichiro

Publication type:

Article

BAP1-related signature predicts benefits from immunotherapy over VEGFR/mTOR inhibitors in ccRCC: a retrospective analysis of JAVELIN Renal 101 and checkmate-009/010/025 trials.

Published in:

Cancer Immunology, Immunotherapy, 2023, v. 72, n. 8, p. 2557, doi. 10.1007/s00262-023-03424-4

By:

Liu, Kan;
Huang, Yan;
Xu, Yu;
Wang, Guoqiang;
Cai, Shangli;
Zhang, Xu;
Shi, Taoping

Publication type:

Article

Correction to: IL‑17A promotes fatty acid uptake through the IL‑17A/IL‑17RA/ p‑STAT3/FABP4 axis to fuel ovarian cancer growth in an adipocyte‑rich microenvironment.

Published in:

2023

By:

Yu, Chunyan;
Niu, Xiulong;
Du, Yongrui;
Chen, Yan;
Liu, Xiaomei;
Xu, Lingling;
Iwakura, Yoichiro;
Ma, Xiaoxia;
Li, Yan;
Yao, Zhi;
Deng, Weimin

Publication type:

Correction Notice

Works matching IS 03407004 AND DT 2023 AND VI 72 AND IP 8

Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors.

Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cancer immunobiology.

Enhanced HPV16 E6/E7<sup>+</sup> tumor eradication via induction of tumor-specific T cells by therapeutic vaccination with virosomes presenting synthetic long peptides.

Sequential CAR T cell and targeted alpha immunotherapy in disseminated multiple myeloma.

Brachyury-targeted immunotherapy combined with gemcitabine against head and neck cancer.

Exploiting docetaxel-induced tumor cell necrosis with tumor targeted delivery of IL-12.

Improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mRNA sequencing and single-cell RNA-sequencing.

Correction to: Increased TIGIT expressing NK cells with dysfunctional phenotype in AML patients correlated with poor prognosis.

Single-center phase 2 study of PD-1 inhibitor combined with DNA hypomethylation agent + CAG regimen in patients with relapsed/refractory acute myeloid leukemia.

Cytokine profiling identifies circulating IL-6 and IL-15 as prognostic stratifiers in patients with non-small cell lung cancer receiving anti-PD-1/PD-L1 blockade therapy.

Massively recruited sTLR9<sup>+</sup> neutrophils in rapidly formed nodules at the site of tumor cell inoculation and their contribution to a pro-tumor microenvironment.

Characterizing the tumor immune microenvironment of ependymomas using targeted gene expression profiles and RNA sequencing.

Safety and efficacy of the anti-PD1 immunotherapy with nivolumab in trichoblastic carcinomas.

Phenotypic and functional analysis in HER2+ targeted therapy of human NK cell subpopulation according to the expression of FcεRIγ and NKG2C in breast cancer patients.

The pathogenetic significance of exhausted T cells in a mouse model of mature B cell neoplasms.

Self-assembled nanoparticles based on DNA origami and a nitrated T helper cell epitope as a platform for the development of personalized cancer vaccines.

Nervous regulation: beta-2-adrenergic signaling in immune homeostasis, cancer immunotherapy, and autoimmune diseases.

Cytotoxicity of CD19-CAR-NK92 cells is primarily mediated via perforin/granzyme pathway.

Engineered murine IL-21-secreting leukemia cells induce granzyme B<sup>+</sup> T cells and CD4<sup>+</sup>CD44<sup>+</sup>CD62L<sup>−</sup> effector memory cells while suppressing regulatory T cells, leading to long-term survival.

Identification of a novel immune checkpoint molecule V-set immunoglobulin domain-containing 4 that leads to impaired immunity infiltration in pancreatic ductal adenocarcinoma.

Switchable CAR T cell strategy against osteosarcoma.

Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma.

Immunoreactivity to WT1 peptide vaccine is associated with prognosis in elderly patients with acute myeloid leukemia: follow-up study of randomized phase II trial of OCV-501, an HLA class II-binding WT1 polypeptide.

Characteristic differences in the abundance of tumor-infiltrating lymphocytes and intratumoral developing T cells in thymoma, with special reference to PD-1 expression.

Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations.

BAP1-related signature predicts benefits from immunotherapy over VEGFR/mTOR inhibitors in ccRCC: a retrospective analysis of JAVELIN Renal 101 and checkmate-009/010/025 trials.

Correction to: IL‑17A promotes fatty acid uptake through the IL‑17A/IL‑17RA/ p‑STAT3/FABP4 axis to fuel ovarian cancer growth in an adipocyte‑rich microenvironment.